Hugo ten Cate


Prof. Hugo ten Cate graduated in Medicine at the University of Amsterdam in 1987. The title of his PhD thesis was 'Clinical and experimental studies with a low molecular weight heparinoid'. Hugo had his post-doctoral training at the laboratory of Prof. Robert Rosenberg and Dr Kenneth Bauer at the Beth Israel Hospital and Harvard Medical School Boston on mechanisms of inflammation associated coagulation activity (1988-1990). He completed his internal medicine training in 1996 and became a general internist in conjunction with research at Academic Medical Center (laboratory of Experimental Internal medicine, Prof. Pieter Reitsma). He received a Clinical Established Investigator grant from the Dutch Heart Foundation in 1998.

In 2002, Hugo ten Cate was appointed Professor of Clinical Thrombosis and Haemostasis at CARIM. In addition, Prof. ten Cate was appointed adjunct professor at the Center for Thrombosis and Haemostasis (CTH) at Gutenberg University Medical Center, Mainz, Germany in 2017

Since the transfer to CARIM in 2002 his research focus shifted from coagulation-inflammation research in sepsis models, to the broader field of cardiovascular (CV) disease (atherothrombosis and 'thrombo-inflammation'). A specific focus of current research is the pleiotropic actions of coagulation proteases in atherosclerosis, atherothrombosis and ischemia reperfusion injury. Clinical research is aimed at chronic thrombotic disease including peripheral artery disease, high risk patients with coronary disease on antithrombotic medication and, together with Dr Arina ten Cate-Hoek, on venous thrombosis and post thrombotic syndrome (PTS). He is workpackage leader in CVON consortia RACE-5 (coagulation and its impact on atrial fibrillation) and CONTRAST (acute ischemic stroke) and involved in the ITN consortia TAPAS and TICARDIO. His group has an ongoing target finding programme with Bayer (steered from CARIM by Dr Henri Spronk and Prof. Hugo ten Cate) as well as with 2M (on POC development).

Department of Biochemistry
Department of Internal Medicine
Universiteitssingel 50, 6229 ER Maastricht
PO Box 616, 6200 MD Maastricht
Room number: 4.344
T: +31(0)43 388 42 62

  • 2022
    • Baidildinova, G., Ten Cate, V., Nagler, M., Panova-Noeva, M., Rapp, S., Köck, T., Prochaska, J. H., Heitmeier, S., Gerdes, C., Schwers, S., Konstantinides, S. V., Münzel, T., Espinola-Klein, C., Lackner, K. J., Spronk, H. M. N., Ten Cate, H., van der Meijden, P. E. J., Leineweber, K., Wild, P. S., & Jurk, K. (2022). Subtype-specific plasma signatures of platelet-related protein releasate in acute pulmonary embolism. Thrombosis Research, 220, 75-87.
    • Ghossein-Doha, C., Wintjens, M. S. J. N., Janssen, E. B. N. J., Klein, D., Heemskerk, S. C. M., Asselbergs, F. W., Birnie, E., Bonsel, G. J., van Bussel, B. C. T., Cals, J. W. L., Ten Cate, H., Haagsma, J., Hemmen, B., van der Horst, I. C. C., Kietselaer, B. L. J. H., Klok, F. A., de Kruif, M. D., Linschoten, M., van Santen, S., ... van Kuijk, S. M. J. (2022). Prevalence, pathophysiology, prediction and health-related quality of life of long COVID: study protocol of the longitudinal multiple cohort CORona Follow Up (CORFU) study. BMJ Open, 12(11), [e065142].
    • Nagy, M., van der Meijden, P. E. J., Glunz, J., Schurgers, L., Lutgens, E., Ten Cate, H., Heitmeier, S., & Spronk, H. M. H. (2022). Integrating Mechanisms in Thrombotic Peripheral Arterial Disease. Pharmaceuticals, 15(11), [1428].
    • Wauthier, L., Favresse, J., Hardy, M., Douxfils, J., Le Gal, G., Roy, P-M., van Es, N., Ay, C., Ten Cate, H., Vander Borght, T., Dupont, M. V., Lecompte, T., Lippi, G., & Mullier, F. (2022). D-dimer Testing in Pulmonary Embolism with a Focus on Potential Pitfalls: A Narrative Review. Diagnostics, 12(11), [2770].
    • Kremers, B. M. M., Posma, J. N., Heitmeier, S., Glunz, J., Ten Cate, H., Pallares Robles, A., Daemen, J. H. C., Ten Cate-Hoek, A. J., Mees, B. M. E., & Spronk, H. M. H. (2022). Discovery of four plasmatic biomarkers potentially predicting cardiovascular outcome in peripheral artery disease. Scientific Reports, 12(1), [18388].
    • Willers, A., Swol, J., Van Kuijk, S. M. J., Buscher, H., McQuilten, Z., Ten Cate, H., Rycus, P. T., McKellar, S., Lorusso, R., & Tonna, J. E. (2022). HEROES V-A-HEmoRrhagic cOmplications in veno-arterial Extracorporeal life Support-Development and internal validation of a multivariable prediction model in adult patients. Artificial Organs, 46(11), 2266-2283.
    • Willems, L. H., Thijssen, D. H. J., Groh, L. A., Kooijman, N. I., Ten Cate, H., Spronk, H. M. H., Donders, A. R. T., Van der Vijver-Coppen, R. J., van Hoek, F., Nagy, M., Reijnen, M. M. P. J., & Warle, M. C. (2022). Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial. Frontiers in cardiovascular medicine, 9, [979819].
    • van de Berg, T. W., Mulder, M. M. G., Alnima, T., Nagy, M., van Oerle, R., Beckers, E. A. M., Hackeng, T. M., Hulshof, A. M., Sels, J. W. E. M., Henskens, Y. M. C., van der Horst, I. C. C., ten Cate, H., Spronk, H. M. H., van Bussel, B. C. T., & Dutch COVID & Thrombosis Coalition (2022). Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort. Frontiers in cardiovascular medicine, 9, [929284].
    • van Paridon, P. C. S., Panova-Noeva, M., van Oerle, R., Schulz, A., Prochaska, J. H., Arnold, N., Schmidtmann, I., Beutel, M., Pfeiffer, N., Munzel, T., Lackner, K. J., ten Cate, H., Wild, P. S., & Spronk, H. M. H. (2022). Lower levels of vWF are associated with lower risk of cardiovascular disease. Research and practice in thrombosis and haemostasis, 6(7), [e12797].
    • Haas, S., Farjat, A. E., Pieper, K., Ageno, W., Angchaisuksiri, P., Bounameaux, H., Goldhaber, S. Z., Goto, S., Mantovani, L., Prandoni, P., Schellong, S., Turpie, A. G. G., Weitz, J. I., MacCallum, P., Cate, H. T., Panchenko, E., Carrier, M., Jerjes-Sanchez, C., Gibbs, H., ... GARFIELD-VTE Investigators (2022). On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease. TH open : companion journal to thrombosis and haemostasis, 6(4), e354-e364.